Literature DB >> 24198065

Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.

Sachin Gupta1, James M Termini, Saravana Kanagavelu, Geoffrey W Stone.   

Abstract

TNF superfamily ligands play a critical role in the regulation of adaptive immune responses, including the costimulation of dendritic cells, T cells, and B cells. This costimulation could potentially be exploited for the development of prophylactic vaccines and immunotherapy. Despite this, there have been only a limited number of reports on the use of this family of molecules as gene-based adjuvants to enhance DNA and/or viral vector vaccines. In addition, the molecule latent membrane protein 1 (LMP1), a viral mimic of the TNF superfamily receptor CD40, provides an alternative approach for the design of novel molecular adjuvants. Here, we discuss advances in the development of recombinant TNF superfamily ligands as adjuvants for HIV vaccines and as cancer immunotherapy, including the use of LMP1 and LMP1-CD40 chimeric fusion proteins to mimic constitutive CD40 signaling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24198065      PMCID: PMC3967553          DOI: 10.1007/s12026-013-8443-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  65 in total

1.  Constitutive CD40L expression on B cells prematurely terminates germinal center response and leads to augmented plasma cell production in T cell areas.

Authors:  Anna Bolduc; Eugene Long; Dale Stapler; Marilia Cascalho; Takeshi Tsubata; Pandelakis A Koni; Michiko Shimoda
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

Review 2.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 3.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

4.  EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Helena Schmidtmayerova; Victoria Snarsky; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Leukoc Biol       Date:  2011-05-17       Impact factor: 4.962

5.  Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.

Authors:  Nicola Winstone; Aaron J Wilson; Gavin Morrow; Cesar Boggiano; Maria J Chiuchiolo; Mary Lopez; Marina Kemelman; Arielle A Ginsberg; Karl Mullen; John W Coleman; Chih-Da Wu; Sandeep Narpala; Ian Ouellette; Hansi J Dean; Feng Lin; Niranjan Y Sardesai; Holly Cassamasa; Dawn McBride; Barbara K Felber; George N Pavlakis; Alan Schultz; Michael G Hudgens; C Richter King; Timothy J Zamb; Christopher L Parks; Adrian B McDermott
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

Review 6.  Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Authors:  Chao Wang; Gloria H Y Lin; Ann J McPherson; Tania H Watts
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 7.  B cell receptor and BAFF receptor signaling regulation of B cell homeostasis.

Authors:  Wasif N Khan
Journal:  J Immunol       Date:  2009-09-15       Impact factor: 5.422

8.  Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Richard S Kornbluth
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

9.  Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Andrew R Rahmberg; Richard S Kornbluth; David T Evans; Geoffrey W Stone
Journal:  Retrovirology       Date:  2011-05-18       Impact factor: 4.602

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more
  3 in total

1.  A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.

Authors:  Roy Rampling; Sharon Peoples; Paul J Mulholland; Allan James; Omar Al-Salihi; Christopher J Twelves; Catherine McBain; Sarah Jefferies; Alan Jackson; Willie Stewart; Juha Lindner; Sarah Kutscher; Norbert Hilf; Lesley McGuigan; Jane Peters; Karen Hill; Oliver Schoor; Harpreet Singh-Jasuja; Sarah E Halford; James W A Ritchie
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

2.  Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice.

Authors:  Evgeniya V Shmeleva; Geoffrey L Smith; Brian J Ferguson
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

3.  Adenoviral delivery of soluble ovine OX40L or CD70 costimulatory molecules improves adaptive immune responses to a model antigen in sheep.

Authors:  José M Rojas; Carolina Mancho; Andrés Louloudes-Lázaro; Daniel Rodríguez-Martín; Miguel Avia; Santiago Moreno; Noemí Sevilla; Verónica Martín
Journal:  Front Cell Infect Microbiol       Date:  2022-09-23       Impact factor: 6.073

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.